Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Aristotle Value Equity Fund Howard Gleicher | “We first invested in Danaher, a company focused on biotechnology, life sciences and diagnostics, in the second quarter of 2016, attracted by its disciplined capital allocation, differentiated operating culture and consistent FREE cash flow generation. The business is distinguished by a portfolio of market-leading franchises and a high mix of recurring consumables revenue tied to a large installed base. Its differentiated operating culture, anchored by the Danaher Business System (DBS), has historically enabled the company to be a highly effective acquirer, consistently integrating new businesses, expanding margins and driving strong FREE cash flow generation. Over our decade-long holding period, Danaher successfully transformed itself from a diversified industrial company into a more focused healthcare business. This evolution included the spinoffs of Fortive, Envista, and Veralto, as well as the acquisition and integration of key assets such as Pall, Cepheid and Cytiva. The company also increased the contribution from recurring revenue and workflow-based solutions embedded in customer operations, which contributed to the durability and predictability of the business. More recently, as Danaher has shifted further into more complex, innovation-driven end markets, the application of DBS appears to be less differentiated than it was in Danaher's traditional manufacturing-oriented businesses. Success in these new end markets is increasingly driven by scientific innovation, faster product cycles and more specialized customer requirements. At the same time, increased scale and a more centralized organizational structure appear to be limiting flexibility at the business unit level, reducing the speed and effectiveness with which opportunities can be pursued. While we continue to view Danaher as a high-quality business, we believe much of our original investment thesis has now been realized, with fewer company-specific catalysts ahead. Accordingly, we elected to exit the position and redeploy the proceeds into what we view as a more attractive opportunity in Edwards Lifesciences.” | BULL | Q2 2026 Aug 10, 2026 | View Pitch |
Aristotle/Saul Global Equity Fund Portfolio Manager | “We first invested in Danaher, a company focused on biotechnology, life sciences and diagnostics, in the first quarter of 2016, attracted by its disciplined capital allocation, differentiated operating culture and consistent FREE cash flow generation. The business is distinguished by a portfolio of market-leading franchises and a high mix of recurring consumables revenue tied to a large installed base. Its differentiated operating culture, anchored by the Danaher Business System (DBS), has historically enabled the company to be a highly effective acquirer, consistently integrating new businesses, expanding margins and driving strong FREE cash flow generation. Over our decade-long holding period, Danaher successfully transformed itself from a diversified industrial company into a more focused healthcare business. This evolution included the spinoffs of Fortive, Envista and Veralto, as well as the acquisition and integration of key assets such as Pall, Cepheid and Cytiva. The company also increased the contribution from recurring revenue and workflow-based solutions embedded in customer operations, which contributed to the durability and predictability of the business. More recently, as Danaher has shifted further into more complex, innovation-driven end markets, the application of DBS appears to be less differentiated than it was in Danaher's traditional manufacturing-oriented businesses. Success in these new end markets is increasingly driven by scientific innovation, faster product cycles and more specialized customer requirements. At the same time, increased scale and a more centralized organizational structure appear to be limiting flexibility at the business unit level, reducing the speed and effectiveness with which opportunities can be pursued. While we continue to view Danaher as a high-quality business, we believe much of our original investment thesis has now been realized, with fewer company-specific catalysts ahead. Accordingly, we elected to exit the position and redeploy the proceeds into what we view as more attractive opportunities.” | BULL | Q2 2026 Aug 10, 2026 | View Pitch |
Zeno Zeno Equity Partners LLP | “In this letter, we will argue that our largest position, Danaher, is a precise manifestation of this archetype of business, clearly demonstrating market power and a rewarding reinvestment opportunity. We will also demonstrate that these are resilient and sustainable attributes that are not properly reflected in the share price, giving us an opportunity to earn an above normal rate of risk-adjusted return. The Biotechnology segment is Danaher's crown jewel, formed through the remarkably successful acquisition of GE's biopharma assets in 2020 and the subsequent integration of Pall's bioprocessing business in 2023. The assets operate under the Cytiva brand, generating ~30% of Danaher's revenues but closer to ~40% of profits. Cytiva sells the equipment and consumables used in bioprocessing, which means the manufacturing of large-molecule drugs (often called biologics) under a classic razor-razorblade model – an instrument is installed almost at cost, with all the money made on high-margin consumables over the contract life. Cytiva has 36% market share, but more importantly it leads the chromatography purification step with an estimated ~70% share. Chromatography is the heart of bioprocessing, where the drug is purified by separating the target molecule from the impurities carried over from the upstream process. As a result, it sets the final purity profile on which the product's safety and efficacy rest, leading to one of the deepest and most expensive lock-ins of the entire process. Little wonder, then, that some chromatography resins carry ~90% gross margins and are a large part of why Danaher earns the best EBIT margins in the industry at ~40%. Danaher's first foray into healthcare was in Diagnostics, which today contributes roughly 40% of revenues and profits. The operating companies in this segment sell instruments and consumables used to perform both clinical and molecular testing. Similar to biotechnology, this is another razor-razorblade, recurring revenue business model, with an estimated 90% of sales coming from higher-margin consumables. Among suppliers Danaher stands out with industry-leading 29% segment EBIT margins, converting over 90% of divisional profits to cash and earning a marginal return in excess of 30% over the past decade. It is worth mentioning that Danaher didn't just buy good assets in diagnostics; rather, it created significant value in successfully implementing DBS. Cepheid is a particularly striking example. At acquisition, the business was barely profitable with a consumables scrap rate of 25%, meaning one-in-four cartridges manufactured were thrown away. Danaher managed to reduce that significantly by implementing lean manufacturing techniques to drive margins to ~30% over a period in which revenue multiplied several-fold. Beckman Diagnostics is another great example, which has been propelled from share donor to share gainer, and we see fertile ground for further operational improvement with the recent ten-billion-dollar Masimo deal which closed last month. The story in Life Sciences which constitutes the remaining ~20% of profits is more convoluted. This is the most diversified segment of the three, selling instruments, consumables and services mostly used in drug discovery with some additional exposure to various industrial and clinical applications. The division earns a low twenties operating margin with ~90% cash conversion. Recurring revenues are still very relevant, but a lower portion of sales compared to the other divisions at ~65%. Having acquired IDT in 2018, Danaher made a much larger bet on the space by acquiring Aldevron in 2021 for almost $10bn. Yet, fast-forward five years, and COVID volumes have plummeted, while the promise of genomics has faced more hurdles than anticipated. Gene therapies have largely remained confined to niche, rare-disease populations, and cell therapies struggle with the complications of moving to 'off-the-shelf' solutions, the key to achieving scale, bringing down costs, and addressing large populations. The mRNA platform, meanwhile, has encountered difficulties being applied beyond COVID. In addition, competitors developed similar capabilities faster than anticipated, widening the range of outcomes. All in all, Aldevron has resulted in significant value destruction, and the chances of achieving a satisfactory return now look thin. Two years later, Danaher acquired Abcam for $5.7bn, a supplier of antibodies and reagents used in research across academia, pharma, and diagnostics. This acquisition, however, has also proved disappointing so far. While DBS worked as expected, expanding margins by five percentage-points in just two years, Abcam's top line growth has been underwhelming as Trump's policies throughout 2025 exacerbated an already weakening research market. Although it's probably still too early to judge this deal as a failure, a rather optimistic scenario is required from here just to deliver a sufficient return. Taking into consideration what it got right and what it got wrong in the construction of Danaher 4.0 we are confident the firm will continue to compound at very attractive returns for a very long time. Disregarding ~40 years of good decisions does not seem rational to us. At a ~5% free-cash-flow yield for a combined business we think can credibly deliver high-single-digit to low-double-digit earnings growth over the next decade, we feel it offers unusually compelling risk-adjusted return characteristics for our investor's capital.” | NEUTRAL | Q2 2026 Jul 25, 2026 | View Pitch |
Zeno Zeno Equity Partners LLP | “But what happens when a business model, built on what is second to none execution and a proven track record of capital allocation, starts to show signs of exhaustion? And what if this happens after the stock has compounded at more than 20% per year for 20 years and trades at a high multiple, praised by analysts and investors as one of the great compounders of the last 30 years? In our experience, most companies, led by executives and boards, will double down on what has been a winning strategy, trying to improve at the margin, doing whatever they can to keep the momentum of the shares and the high valuation going. But how would a founder or a generational owner (someone who knows they will own the stock for decades) tackle this situation? While it is impossible to generalize, we believe that we have a very good example of how real owners assess risk and make decisions focused on the long-term success even if that means departing from a formula that has worked incredibly well for decades. It is particularly interesting given that the company in focus, Danaher, happens to be the largest position in Zeno Investment Fund. In the last few years we have had the opportunity to have many high-level conversations with the company which have informed the view we are sharing here. Danaher is one of the most celebrated investment cases of the last 30 years. It has also been the object of a myriad of academic business cases tracing its history, deals, culture and highly successful Danaher Business System, a collection of practices and management tools that have significantly impacted the performance of the businesses acquired by the conglomerate over the years. Given such exhaustive coverage, we will not spend these pages on yet another detailed deep dive on these topics. Instead, we want to examine how and why Danaher has threaded a different path from so many other contemporaneous businesses. BSD Analysis: Danaher is operational excellence disguised as a conglomerate, with the Danaher Business System doing the heavy lifting year after year. Its portfolio of life sciences and diagnostics businesses sits upstream of innovation rather than downstream of product risk. Demand softness tied to biotech funding cycles has pressured sentiment, not the franchises themselves. Margins remain resilient because DBS forces discipline when volumes wobble. Investors expect constant M&A magic and miss the value of steady execution. Cash flow supports reinvestment without leverage stress. As funding normalizes, utilization rebounds quickly. This is execution as a moat, not deal-making theater. Quality compounds quietly.” | BULL | Q4 2025 Jan 21, 2026 | View Pitch |
ACATIS Investment Dr. Hendrik Leber | “This stock, a specialist for life sciences and diagnostics, was sold because the high valuation does not offer a lot of upward potential at the moment, considering the moderate growth outlook and stagnating equipment sales. At this time, there are other companies in this segment with more impressive operations. BSD Analysis: Danaher's moat is process excellence—DBS turns acquisitions into disciplined, recurring cash machines. Consumables and services smooth cycles, even if instrument demand wobbles. Portfolio rotation keeps growth alive while shedding laggards. Pricing power comes from mission-critical positioning, not brand flash. Biopharma funding cycles inject short-term noise. Capital allocation credibility is the real asset. Operating leverage emerges when volume returns. The bull case is normalized lab spend with disciplined integration. Danaher compounds by running better systems than competitors.” | BEAR | Q4 2025 Jan 12, 2026 | View Pitch |
Baron Durable Advantage Fund Alex Umansky | “We also added to our position in Danaher Corporation. Danaher supplies life science tools for lab research, genomics, and bioprocessing/drug manufacturing. It also offers instruments to run clinical diagnostics in large core labs, hospitals, and at the point of care. The stock has come under pressure in recent years along with the rest of the life science tools space due to several reasons: First, biotechnology funding had been constrained, and earlier-stage, discovery research had been under particular pressure. In addition, uncertainty around pharmaceutical tariffs and Most-Favored-Nation drug pricing had been a headwind for large pharmaceutical companies. Second, National Institutes of Health (NIH) funding has been another area of softness, given the priority of the current administration in cutting university grant funding. Finally, China has been a weak geography. For Danaher, their clinical diagnostics business has been subject to volume-based procurement, which is leading to pricing pressure in the region. We view these as cyclical factors that create an opportunity for long-term investors. Recently, we have seen green shoots emerge: • Pharmaceutical companies have announced heavy investments in domestic manufacturing in response to the Trump Administration's push for reshoring, which opens up a large capital equipment purchasing opportunity. Given Danaher's dominant positioning in multiple end markets, particularly their scaled bioprocessing portfolio, we believe the company stands to benefit from the upcoming capex cycle. Drug production is a highly regulated industry, and Danaher is a trusted brand that is spec'ed into production workflows. • On NIH, the latest outlays data has seen a rebound into the end of calendar year 2025, which is promising. Regardless, government/academic research is only a low single-digit percentage of Danaher's business, so we believe Danaher is less exposed to fluctuations in NIH funding policy. • China has also began normalizing for Danaher within diagnostics. Beyond diagnostics, the life science market in China has been robust with new innovations that multinationals are licensing. We continue to see Danaher as a quality compounder with long-term revenue growth of high single digits, 40% operating profit fall-through, and double-digit EPS growth. BSD Analysis: Danaher is life sciences and diagnostics infrastructure engineered for long-cycle compounding, not quarter-to-quarter excitement. Its tools and consumables sit inside regulated workflows where uptime and reliability matter more than price. Funding cycles create revenue noise, but installed base demand never disappears. Investors fixate on near-term deceleration and miss how much recurring service and consumables revenue anchors cash flow. The Danaher Business System keeps margins structurally high through relentless execution, not financial engineering. Portfolio recycling steadily upgrades asset quality over time. Capital allocation favors returns, not empire building. This is scientific productivity monetized with discipline while sentiment chases shinier narratives.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Brown Advisory Large-Cap Growth Strategy Brown Advisory LLC | “Danaher was added as the company showed signs of renewed momentum across its businesses. Nearly 80% of revenue comes from recurring sources, supporting stability. Danaher maintains strong competitive advantages and industry-leading margins. Improving end-market conditions are accelerating demand for life sciences tools. The company's execution track record remains best-in-class. BSD Analysis: Danaher is life sciences infrastructure optimized for long-cycle compounding, not quarter-to-quarter growth optics. Its tools are embedded in regulated workflows where downtime and switching risk are unacceptable. Funding cycles create noise, but installed base demand never disappears. Investors fixate on near-term deceleration and miss the durability of consumables and service revenue. The Danaher Business System keeps margins structurally high. Capital recycling steadily upgrades portfolio quality. This is scientific productivity monetized with discipline and patience.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Mar Vista US Quality Silas Myers, Brian Massey | “After lagging through the first three quarters of 2025, Danaher's (DHR) stock rebounded during Q4 as bioprocessing, life science, and diagnostics demand continued to recover from a cyclical trough. On the 3Q25 call, management established conservative 2026 growth expectations. Revenue is expected to continue to lag long-term trends at 3-6% but improve throughout the year. Operating leverage should drive high single digit EPS growth. The company's strong balance sheet and capital deployment strategy should provide accretive growth for the foreseeable future. BSD Analysis: Danaher is presented as a high-quality platform exiting a cyclical trough, with bioprocessing, life science, and diagnostics demand recovering. Management's conservative 2026 view still implies improving revenue cadence through the year, and operating leverage should convert that into high single-digit EPS growth. Danaher's balance sheet and proven capital deployment add a second engine—accretive M&A—to sustain long-run compounding. The setup is attractive if customer destocking truly normalizes and bioprocessing utilization improves. Key risks are a slower recovery, renewed budget pressure in life science tools, or weaker-than-expected operating leverage. The pitch is fundamentally bullish on the platform and on-cycle reinvestment discipline.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Hedged Equity Fund ArrowMark Colorado Holdings LLC | “Danaher Corp. is a global leader in life sciences and diagnostics, with a strong presence in bioprocessing, medical research, and clinical diagnostics. We hold Danaher for its competitive positioning in growing end-markets, its underappreciated bioprocessing franchise, and its consistent free cash flow generation. During the quarter, shares rose on signs of stabilization in their bioprocessing segment and results that exceeded expectations. Management also reaffirmed its forward guidance, signaling confidence in the portfolio's resilience despite broader market challenges. BSD Analysis: Danaher is execution excellence disguised as a conglomerate. Its life sciences and diagnostics businesses sit upstream of innovation, not downstream of product risk. Biotech funding cycles create noise, not thesis breaks. The Danaher Business System enforces margin discipline when volumes wobble. Investors expect constant M&A magic and miss steady compounding. Cash flow funds reinvestment without balance-sheet stress. As utilization recovers, earnings snap back quickly. This is operational rigor as a moat.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Madison Sustainable Equity Fund Maya Bittar, Dave Geisler | “Danaher reported mixed organic growth with flat overall revenue, but its Biotechnology segment delivered 7% organic growth, marking a strong recovery from prior declines. Life Sciences and Diagnostics segments remained pressured by weaker instrument demand and procurement changes in China. The company expects low-single-digit revenue growth for the full year and believes it can largely offset tariff impacts. BSD Analysis: Danaher is a high-quality, R&D-driven life science tools behemoth whose stock is a conviction bet on the long-term, non-cyclical growth of bioprocessing and diagnostics. The core moat is the Danaher Business System (DBS), a culture and operating model of continuous improvement that ensures superior margin expansion and integration of acquired assets. The company is successfully executing its strategy of concentrating capital on high-growth areas like bioprocessing and gene editing. Danaher is an indispensable, high-quality compounder whose stability and operational excellence justify its premium valuation.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
